Evidence map›Paper›PMID 37754256›Full record

ArticleCurrent issues in molecular biology2023

Administration of Tamoxifen Can Regulate Changes in Gene Expression during the Acute Phase of Traumatic Spinal Cord Injury.

Eibar E Cabrera-Aldana, Yalbi I Balderas-Martinez, Rafael Velázquez-Cruz, Luis B Tovar-Y-Romo, Rosalba Sevilla-Montoya, Angelina Martínez-Cruz, Claudia Martinez-Cordero, Margarita Valdes-Flores, Monica Santamaria-Olmedo, Alberto Hidalgo-Bravo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Eibar E Cabrera-AldanaDepartment of Genomics Medicine, National Institute of Rehabilitation (INR), Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City 14389, Mexico.ORCID 0000-0002-1280-8088
Yalbi I Balderas-MartinezLaboratorio de Biología Computacional, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, Mexico.ORCID 0000-0001-6400-0526
Rafael Velázquez-CruzGenomics of Bone Metabolism Laboratory, National Institute of Genomic Medicine (INMEGEN), Periférico Sur 4809, Arenal Tepepan, Mexico City 14610, Mexico.ORCID 0000-0003-4515-0777
Luis B Tovar-Y-RomoDepartment of Molecular Neuropathology, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad Universitaria, Circuito Exterior s/n, Mexico City 04510, Mexico.ORCID 0000-0003-2605-1378
Rosalba Sevilla-MontoyaReproductive Research and Perinatal Health Department, National Institute of Perinatology, Montes Urales 800, Lomas de Virreyes, Mexico City 11000, Mexico.
Angelina Martínez-CruzDepartment of Experimental Surgery, Proyecto Camina, A.C. 4430 Calz. Tlalpan, Mexico City 14050, Mexico.
Claudia Martinez-CorderoRegional Hospital of High Specialty of the Bajio, Blvd. Milenio 130, Col. San Carlos la Roncha, León 37660, Guanajuato, Mexico.ORCID 0000-0002-4867-7649
Margarita Valdes-FloresDepartment of Genomics Medicine, National Institute of Rehabilitation (INR), Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City 14389, Mexico.
Monica Santamaria-OlmedoDepartment of Genomics Medicine, National Institute of Rehabilitation (INR), Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City 14389, Mexico.
Alberto Hidalgo-BravoDepartment of Genomics Medicine, National Institute of Rehabilitation (INR), Calzada Mexico-Xochimilco 289, Arenal de Guadalupe, Mexico City 14389, Mexico.ORCID 0000-0003-2506-8784
Gabriel Guízar-SahagúnResearch Unit for Neurological Diseases, Instituto Mexicano del Seguro Social, 330 Avenida Cuauhtémoc, Mexico City 06720, Mexico.
Instituto Nacional de Rehabilitación · MXHospital Regional de Alta Especialidad del Bajío · MXInstituto Nacional de Enfermedades Respiratorias · MXInstituto Nacional de Perinatología · MXMexican Social Security Institute · MXNational Institute of Genomic Medicine · MXUniversidad Nacional Autónoma de México · MX

Funding

Consejo Nacional de Ciencia y Tecnología CB2017-2018 A1-S-54561
6 · The paper itself

Abstract

Traumatic spinal cord injury (SCI) causes irreversible damage leading to incapacity. Molecular mechanisms underlying SCI damage are not fully understood, preventing the development of novel therapies. Tamoxifen (TMX) has emerged as a promising therapy. Our aim was to identify transcriptome changes in the acute phase of SCI and the effect of Tamoxifen on those changes in a rat model of SCI. Four groups were considered: (1) Non-injured without TMX (Sham/TMX-), (2) Non-injured with TMX (Sham/TMX+), (3) injured without TMX (SCI/TMX-), and (4) injured with TMX (SCI/TMX+). Tamoxifen was administered intraperitoneally 30 min after injury, and spinal cord tissues were collected 24 h after injury. Clariom S Assays Array was used for transcriptome analysis. After comparing Sham/TMX- versus SCI/TMX-, 708 genes showed differential expression. The enriched pathways were the SCI pathway and pathways related to the inflammatory response. When comparing SCI/TMX- versus SCI/TMX+, only 30 genes showed differential expression, with no pathways enriched. Our results showed differential expression of genes related to the inflammatory response after SCI, and Tamoxifen seems to regulate gene expression changes in

Indexed as

gene expressioninflammatory responsespinal cord injurytamoxifentranscriptome

Identifiers

PMID37754256
PMCPMC10529143
OpenAlexW4386741726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.